Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients With Advanced Solid Tumors With KRAS G12C Mutation

Trial Profile

A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients With Advanced Solid Tumors With KRAS G12C Mutation

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 31 Jan 2019

At a glance

  • Drugs MRTX 849 (Primary)
  • Indications Colorectal cancer; Non-small cell lung cancer; Solid tumours
  • Focus Adverse reactions; Pharmacokinetics; Proof of concept
  • Sponsors Mirati Therapeutics
  • Most Recent Events

    • 15 Jan 2019 According to a Mirati Therapeutics media release, first patient has been dosed in the trial.
    • 19 Dec 2018 Status changed from planning to recruiting.
    • 29 Nov 2018 According to a Mirati Therapeutics media release, Investigational New Drug (IND) Application has been approved. company expects first patient to be enrolled in the trial by January 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top